Continuous Glucose Monitoring Utilization for Patients With Diabetes (CGD-E)

The percentage of persons 18–75 years of age with diabetes on insulin therapy who have evidence of continuous glucose monitoring (CGM) utilization during the measurement period.

Why It Matters

Diabetes is one of the most costly and highly prevalent chronic diseases in the United States. Approximately 40 million U.S. adults have diabetes; 11 million of these cases are undiagnosed.¹ Complications from the disease cost the country nearly $640B annually.² Diabetes is the seventh leading cause of death in the U.S. and killed approximately 339,342 people in 2023.¹ Many complications such as heart disease, stroke, blindness, kidney failure and amputation can be prevented if diabetes is detected and addressed in the early stages.

Management of glucose levels in people living with diabetes is vital to prevent serious health problems including heart disease, vision loss and kidney disease.3 CGM systems track glucose levels continuously,4 and the real time data can help prevent short- and long-term complications, support lifestyle changes and enable more precise treatment adjustments by care teams.5 The American Diabetes Association (ADA) recommends CGM use for many people with diabetes, including adults treated with insulin.6 Despite guideline recommendations, CGM use varies across populations. Assessing CGM utilization supports understanding of how guideline recommended CGM is used in diabetes care and provides insight into variation in real world practice.

Historical Results – National Averages

Performance results for this measure are currently unavailable.